Tigecycline – Injection products

FDA-Identified Interpretive Criteria

	Minimum Inhibitory Concentrations (mcg/mL)			Disk Diffusion (zone diameter in mm)
Pathogen	S	I	R	S	I	R
Staphylococcus aureus (including methicillin-resistant isolates)	≤0.5^a	-	-	≥19	-	-
Streptococcus spp. other than S. pneumoniae	≤0.25^a	-	-	≥19	-	-
Streptococcus pneumoniae	≤0.06^a	-	-	≥19	-	-
Enterococcus faecalis (vancomycin-susceptible isolates)	≤0.25^a	-	-	≥19	-	-
Enterobacterales^b	≤2	4	≥8	≥19	15-18	≤14
Haemophilus influenzae	≤0.25^a	-	-	≥19	-	-
Anaerobes^c	≤4	8	≥16	-	-	-

S = Susceptible; I = Intermediate; R = Resistant
For disk diffusion, use paper disks impregnated with 15 mcg tigecycline

^a The current absence of resistant isolates precludes defining any results other than “Susceptible.” Isolates yielding MIC results suggestive of “Nonsusceptible” category should be submitted to reference laboratory for further testing.
^b Tigecycline has decreased in vitro activity against Morganella spp., Proteus spp. and Providencia spp.
^c Agar dilution